Raymond James & Associates Trims Stock Position in Exact Sciences Co. (NASDAQ:EXAS)

Raymond James & Associates trimmed its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 25.6% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 56,607 shares of the medical research company’s stock after selling 19,518 shares during the period. Raymond James & Associates’ holdings in Exact Sciences were worth $3,856,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Itau Unibanco Holding S.A. purchased a new position in shares of Exact Sciences during the 2nd quarter worth approximately $29,000. V Square Quantitative Management LLC purchased a new position in shares of Exact Sciences during the 3rd quarter worth approximately $47,000. EverSource Wealth Advisors LLC raised its stake in shares of Exact Sciences by 92.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 708 shares of the medical research company’s stock worth $49,000 after buying an additional 340 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Exact Sciences by 48.4% during the 2nd quarter. GAMMA Investing LLC now owns 1,362 shares of the medical research company’s stock worth $58,000 after buying an additional 444 shares in the last quarter. Finally, EntryPoint Capital LLC purchased a new position in shares of Exact Sciences during the 1st quarter worth approximately $67,000. 88.82% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, EVP Brian Baranick sold 929 shares of the stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $70.00, for a total transaction of $65,030.00. Following the sale, the executive vice president now owns 13,687 shares in the company, valued at approximately $958,090. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.36% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Canaccord Genuity Group increased their target price on Exact Sciences from $75.00 to $95.00 and gave the stock a “buy” rating in a research note on Tuesday, October 29th. Wells Fargo & Company began coverage on Exact Sciences in a report on Tuesday, August 27th. They issued an “overweight” rating and a $75.00 price target on the stock. Piper Sandler upped their price target on Exact Sciences from $75.00 to $85.00 and gave the stock an “overweight” rating in a report on Thursday, September 12th. Evercore ISI upped their price target on Exact Sciences from $72.00 to $80.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, Sanford C. Bernstein upped their price target on Exact Sciences from $75.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $80.64.

Exact Sciences Price Performance

Shares of NASDAQ:EXAS opened at $69.80 on Monday. The business’s fifty day moving average price is $66.81 and its two-hundred day moving average price is $56.59. The stock has a market cap of $12.90 billion, a PE ratio of -72.71 and a beta of 1.27. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.98 and a current ratio of 2.17. Exact Sciences Co. has a one year low of $40.62 and a one year high of $79.62.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.